A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects
A20 mRNA therapy effectively alleviates fibrosis by restoring A20 expression and inhibiting TRAF6/NF-κB signaling, while also downregulating DREAM, a previously unrecognized target. This dual-pathway regulation underscores the role of A20 and DREAM as central modulators of fibrotic progression. These findings highlight the potential of A20 mRNA-LNP as a novel therapeutic strategy for SSc, offering a multifaceted approach that may surpass current treatment options by simultaneously targeting interconnected pathogenic pathways.
Authors
- Jin Hyung Park
- Jeong Won Choi
- Sung Ho Jeon (ORCID: https://orcid.org/0000-0001-5982-140X)
- A Ram Lee (ORCID: https://orcid.org/0000-0003-2683-1614)
- Jae‐Hwan Nam (ORCID: https://orcid.org/0000-0002-0974-4343)
- Hye Won Kwak
- Hyo‐Jung Park (ORCID: https://orcid.org/0000-0002-1601-7638)
- So Won Lee
- Seon Yeong Lee (ORCID: https://orcid.org/0000-0002-8274-3654)
- Shuang Yang (ORCID: https://orcid.org/0000-0002-4779-8553)
- Mi‐La Cho (ORCID: https://orcid.org/0000-0001-5715-3989)
- Y. Bang
- Se Gyeong Han (ORCID: https://orcid.org/0009-0007-7041-2333)
Institutions
- Hanall Biopharma (South Korea) (KR)
- The Catholic University of Korea Bucheon St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1665998
- Citations
- 1
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.47